Xintela AB Interim Report January – March 2025

Summary of the interim reportThe “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. The GroupFirst quarter 2025Income amounted to TSEK 140 (299).Loss before tax totalled TSEK 10,427 (loss: 10,997).Loss per share was SEK 0.02 (loss: 0.02). The Parent companyFirst quarter 2025Income amounted to TSEK 140 (299).Loss before tax totalled TSEK 8,574 (loss: 9,688). Significant […]

Xintela AB publishes Annual Report 2024

Xintela AB (publ) announces that the company’s annual report for 2024 is published on the company’s website www.xintela.se and is attached to this announcement. Link to the annual report: https://www.xintela.se/en/report-archive Contacts Xintela AB (publ)Evy Lundgren-Åkerlund, CEOTel: +46 46 275 65 00Email: evy@xintela.seMedicon Village223 81 Lund, Swedenwww.xintela.se About Xintela Xintela develops medical products in stem cell […]

Xintela and EQGen Biomedical sign collaboration and license agreement for veterinarian stem cell products

Xintela and EQGen Biomedical Inc. (“EQGen”) have signed the definitive collaboration and license agreement, contemplated by their previously announced term sheet, for the development of Xintela’s equine stem cell product EQSTEM® and other animal stem cell products. EQGen gets global rights to Xintela’s stem cell technology for the treatment of veterinary musculoskeletal indications. Xintela and […]

Xintela’s stem cell product XSTEM shows safety and positive efficacy results in knee osteoarthritis clinical study

Xintela’s interim analysis of data from the knee osteoarthritis clinical study shows safety and positive efficacy results, 18 months after treatment with XSTEM. The results demonstrate statistically significant and clinically meaningful improvements in knee pain and knee function. In addition, the results of XSTEM treatment show an improvement in bone structure and also a trend […]

Xintela AB Year-end Report 2024

Summary of the year-end report The “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. The GroupForth quarter 2024Income amounted to TSEK 1,090 (78).Loss before tax totalled TSEK 11,712 (loss: 12,175).Loss per share* was SEK 0.02 (loss: 0.03). Full year 2024Income amounted to TSEK 4,215 (78).Loss before tax totalled TSEK 41,534 (loss: 58,367).Loss […]

Xintela AB Interim Report January – September 2024

Summary of the interim reportThe “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. The GroupThird quarter 2024Income amounted to TSEK 2,822 (0).Loss before tax totalled TSEK 8,049 (loss: 11,953).Loss per share was SEK 0.01 (loss: 0.02). First nine month 2024Income amounted to TSEK 3,125 (0).Loss before tax totalled TSEK 29,821 (loss: 46,192).Loss […]

Xintela’s main owner Flerie undertakes to exercise warrants TO3 of approximately SEK 28 million and provides a bridge loan of SEK 9 million

Xintela AB (publ) (“Xintela” or the “Company”) today announces that the Company’s largest shareholder Flerie Invest AB, which holds approximately 55.5 percent of the number of shares and votes in the Company, has committed to exercise warrants of series TO3 of approximately SEK 28 million during the exercise period beginning on November 25, 2024. Flerie’s […]

Xintela AB Interim Report January – June 2024

Summary of the interim reportThe “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. THE GROUPSecond quarter 2024Income amounted to TSEK 4 (0).Loss before tax totalled TSEK 10,400 (loss: 18,401).Loss per share was SEK 0.02 (loss: 0.06). First half year 2024Income amounted to TSEK 303 (0).Loss before tax totalled TSEK 21,773 (loss: 34,244).Loss […]